Partnerships with leading pharma, academic medical centers and foundations

BostonGene’s AI-powered multiomics platform supports patient care, discovery and drug development

The partnership reflects BostonGene’s commitment to improving patient outcomes through innovative research and data-driven approaches.

Takeda

Takeda will leverage BostonGene's AI-powered multiomics platform in select early-stage clinical trials to enhance trial design, identify biomarker signatures for response and toxicity.

Ottimo Pharma

BostonGene Announces Collaboration with Ottimo Pharma to Optimize and Accelerate Development of First-in-Class PD-1/VEGFR2 Immuno-Oncology Therapy Using AI.

AstraZeneca

BostonGene and AstraZeneca Announce Strategic Collaboration to Advance Foundation Model-Driven Oncology Development

Partners

Thomas Jefferson University

Philadelphia, PA

Transgene

llkirch-Graffenstaden, France

Washington University School of Medicine

St Louis, MO

Weill Cornell Medical College

New York, NY

We help to improve research and analysis

BostonGene’s cloud-based platform integrates multiple AI-based molecular and immune profiling techniques that comprehensively analyze the tumor, microenvironment, and host immunity, uncovering treatable targets to personalize therapy for patients.

Visit BioPharma

Partnership to provide sophisticated data analytics to produce viable treatment options personalized for each patient.